American Society of Hematology

banner image

61st ASH Annual Meeting & Exposition

Late-breaking abstracts are now available in the final annual meeting program.

Learn more
banner image

2020 Highlights of ASH

Discuss the latest developments with leading hematology faculty in nine exciting locations worldwide.

Register today
banner image

Medical Student and Early-Career Investigator Awards

ASH has several sponsored hands-on research opportunities.

Learn more
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 17,000 hematologists working to conquer blood diseases.

Learn more
  • First Industry Datasets Submitted to ASH Research Collaborative Data Hub

    The ASH Research Collaborative has collaborated with two industry leaders, Novartis and Amgen, to include de-identified patient data from three separate studies of nearly 500 patients living with SCD and more than 1,000 patients with multiple myeloma as part of an unprecedented data sharing initiative.

  • ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia

    Today, ASH published new state-of-the art guidelines on the treatment of immune thrombocytopenia (ITP), a rare blood disorder characterized by a decrease in the number of platelets, the part of the blood needed for normal clotting. The guidelines are published in the journal Blood Advances.

  • ASH to Recognize Choosing Wisely Champions at 61st Annual Meeting

    The American Society of Hematology will recognize three Choosing Wisely® Champions, practitioners working to tackle overuse of hematology tests and treatments, at its 61st ASH Annual Meeting in Orlando.

  • Light-to-Moderate Exercise May Bring Benefits for Sickle Cell Disease

    While exercise offers benefits for a wide range of health conditions, it has historically been considered too dangerous for people living with sickle cell disease (SCD). However, a new study published today in the journal Blood adds to mounting evidence that low-to moderate-intensity exercise may be not only safe, but beneficial for these patients.

View all press releases
  • CAR T-cell Therapy: An Update on Coverage and Reimbursement

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • 2018 ASH Advocacy Activities

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

View all policy news
View all Hematologist articles